Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP)
INOVIO Reports Positive Results
The data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) has shown promising results. The trial involved patients who were part of a Phase 1/2 trial and the numbers are quite impressive. By the end of year 2, the number of patients who met the criteria for a Complete Response (CR) increased to 50%, and by year 3, it further increased to 54%. This is a significant improvement compared to the 28% Complete Response rate at the end of the initial 52-week trial.
Long-Term Benefits
It is also worth noting that 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2, and 86% of patients maintained or enhanced ORR into year 3. This shows the potential long-term benefits of treatment with INO-3107 for patients with RRP.
Future Plans
The new durability data is expected to help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease. INOVIO plans to present the data at future scientific conferences and submit it for publication in peer-reviewed journals, further contributing to the research and development in this field.
Impact on Individuals
For individuals affected by Recurrent Respiratory Papillomatosis (RRP), the positive results from the retrospective trial evaluating INO-3107 bring hope for better treatment options and improved outcomes. The increased Complete Response rate and maintenance of Overall Response Rate over multiple years indicate the potential for long-term benefit for patients.
Global Impact
On a global scale, the positive results from the trial have the potential to impact the way RRP is treated and managed worldwide. The new data on the effectiveness of INO-3107 could lead to advancements in the treatment of RRP, ultimately improving patient outcomes and reducing the burden of the disease on healthcare systems globally.
Conclusion
The data from the retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) is promising. The increase in Complete Response rate and maintenance of Overall Response Rate over multiple years demonstrate the potential for long-term benefits for patients. These findings have the potential to make a positive impact on both individuals affected by RRP and the global healthcare community as a whole.
